A clinical trial found a 2.3% incidence of venous thromboembolism in a group of patients taking the drug apixaban, compared with 2.7% in the group receiving enoxaparin and warfarin. Major bleeding occurred in 9.7% of patients in the standard treatment group and 4.3% of patients in the apixaban group. The study in the New England Journal of Medicine concluded that apixaban was as safe and effective as standard therapy in treating blood clots.

Full Story:

Related Summaries